Innate Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Innate Pharma has a total shareholder equity of €51.9M and total debt of €39.1M, which brings its debt-to-equity ratio to 75.3%. Its total assets and total liabilities are €184.2M and €132.3M respectively.
Key information
75.3%
Debt to equity ratio
€39.06m
Debt
Interest coverage ratio | n/a |
Cash | €92.46m |
Equity | €51.90m |
Total liabilities | €132.29m |
Total assets | €184.19m |
Recent financial health updates
No updates
Recent updates
Innate Pharma: Worth A Deeper Look
Jan 11Innate Pharma GAAP EPS of €0.08, revenue of €45.59M
Sep 15Innate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3M
Jul 21Innate Pharma: Leading The NK Cell Immunotherapy Space
Oct 06Innate Pharma: Attractive Price, But Comes With Uncertainty
Jan 29Innate Pharma files $200M equity shelf
Jan 13Innate Pharma gives back US, EU Lumoxiti rights to AZN
Dec 11Innate Pharma reports 9M results
Nov 17EMA grants PRIME tag to Innate Pharma's lacutamab for T-cell lymphoma
Nov 13Financial Position Analysis
Short Term Liabilities: IPHA's short term assets (€148.0M) exceed its short term liabilities (€39.6M).
Long Term Liabilities: IPHA's short term assets (€148.0M) exceed its long term liabilities (€92.7M).
Debt to Equity History and Analysis
Debt Level: IPHA has more cash than its total debt.
Reducing Debt: IPHA's debt to equity ratio has increased from 1.5% to 75.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPHA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IPHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.